Zhang, T., Dhawan, M. S., Healy, P., George, D. J., Oldan, J., Chin, B., & Armstrong, A. J. (2014). Clinical benefit of docetaxel or enzalutamide after progression on first-line abiraterone acetate and prednisone in men with metastatic castration resistant prostate cancer (mCRPC). In Journal of Clinical Oncology (Vol. 32, pp. e16031–e16031). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.e16031

Zhang, Tian, Mallika S. Dhawan, Patrick Healy, Daniel J. George, Jorge Oldan, Bennett Chin, and Andrew J. Armstrong. “Clinical benefit of docetaxel or enzalutamide after progression on first-line abiraterone acetate and prednisone in men with metastatic castration resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 32:e16031–e16031. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.e16031.

Zhang T, Dhawan MS, Healy P, George DJ, Oldan J, Chin B, et al. Clinical benefit of docetaxel or enzalutamide after progression on first-line abiraterone acetate and prednisone in men with metastatic castration resistant prostate cancer (mCRPC). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. e16031–e16031.

Zhang, Tian, et al. “Clinical benefit of docetaxel or enzalutamide after progression on first-line abiraterone acetate and prednisone in men with metastatic castration resistant prostate cancer (mCRPC).” Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. e16031–e16031. Crossref, doi:10.1200/jco.2014.32.15_suppl.e16031.

Zhang T, Dhawan MS, Healy P, George DJ, Oldan J, Chin B, Armstrong AJ. Clinical benefit of docetaxel or enzalutamide after progression on first-line abiraterone acetate and prednisone in men with metastatic castration resistant prostate cancer (mCRPC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. e16031–e16031.